Stanisław Wawrzyniak, Julia Cieśla, Magdalena Woś, Ewa Wołoszyn-Horák, Michał M Masternak, Tomasz Kukulski, Ewa Stępień, Andrzej Tomasik
{"title":"体弱患者心血管风险的表观遗传生物标志物——范围综述","authors":"Stanisław Wawrzyniak, Julia Cieśla, Magdalena Woś, Ewa Wołoszyn-Horák, Michał M Masternak, Tomasz Kukulski, Ewa Stępień, Andrzej Tomasik","doi":"10.3390/cimb47060422","DOIUrl":null,"url":null,"abstract":"<p><p>Epigenetic biomarkers offer promising potential for early identification and risk stratification of frail individuals susceptible to adverse cardiovascular outcomes. This scope review aimed to identify and evaluate epigenetic biomarkers concurrently associated with frailty and increased cardiovascular risk, potentially facilitating more precise patient stratification and treatment decisions. A two-stage literature search was performed using PubMed, Scopus, Web of Science, and Embase databases from the year 2000 through 27 December 2024. Stage 1 identified studies reporting epigenetic biomarkers associated with frailty in blood-derived human samples. Stage 2 assessed cardiovascular relevance by screening the frailty biomarkers identified in Stage 1 for their documented association with cardiovascular diseases. Two independent reviewers conducted screening, data extraction, and risk-of-bias assessments, resolving disagreements via a third reviewer. The primary outcomes were the association of biomarkers with frailty severity and cardiovascular risk. Key epigenetic biomarkers identified included microRNAs (particularly miR-21, miR-146a, miR-451, and miR-92a) and DNA methylation markers (LINE-1 methylation, epigenetic clocks like GrimAge and DunedinPACE, and possibly novel, emerging clocks like DNAmCVDscore and the Smoking Index). Due to specificity limitations, these biomarkers are most promising when used collectively as part of multimarker panels rather than individually. Future research should validate multimarker panels, explore novel biomarkers, and assess clinical integration to optimize precision medicine in frail cardiovascular populations.</p>","PeriodicalId":10839,"journal":{"name":"Current Issues in Molecular Biology","volume":"47 6","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192519/pdf/","citationCount":"0","resultStr":"{\"title\":\"Epigenetic Biomarkers of Cardiovascular Risk in Frail Patients-A Scope Review.\",\"authors\":\"Stanisław Wawrzyniak, Julia Cieśla, Magdalena Woś, Ewa Wołoszyn-Horák, Michał M Masternak, Tomasz Kukulski, Ewa Stępień, Andrzej Tomasik\",\"doi\":\"10.3390/cimb47060422\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Epigenetic biomarkers offer promising potential for early identification and risk stratification of frail individuals susceptible to adverse cardiovascular outcomes. This scope review aimed to identify and evaluate epigenetic biomarkers concurrently associated with frailty and increased cardiovascular risk, potentially facilitating more precise patient stratification and treatment decisions. A two-stage literature search was performed using PubMed, Scopus, Web of Science, and Embase databases from the year 2000 through 27 December 2024. Stage 1 identified studies reporting epigenetic biomarkers associated with frailty in blood-derived human samples. Stage 2 assessed cardiovascular relevance by screening the frailty biomarkers identified in Stage 1 for their documented association with cardiovascular diseases. Two independent reviewers conducted screening, data extraction, and risk-of-bias assessments, resolving disagreements via a third reviewer. The primary outcomes were the association of biomarkers with frailty severity and cardiovascular risk. Key epigenetic biomarkers identified included microRNAs (particularly miR-21, miR-146a, miR-451, and miR-92a) and DNA methylation markers (LINE-1 methylation, epigenetic clocks like GrimAge and DunedinPACE, and possibly novel, emerging clocks like DNAmCVDscore and the Smoking Index). Due to specificity limitations, these biomarkers are most promising when used collectively as part of multimarker panels rather than individually. Future research should validate multimarker panels, explore novel biomarkers, and assess clinical integration to optimize precision medicine in frail cardiovascular populations.</p>\",\"PeriodicalId\":10839,\"journal\":{\"name\":\"Current Issues in Molecular Biology\",\"volume\":\"47 6\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192519/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Issues in Molecular Biology\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.3390/cimb47060422\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Issues in Molecular Biology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.3390/cimb47060422","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
表观遗传生物标志物为易受心血管不良后果影响的虚弱个体的早期识别和风险分层提供了有希望的潜力。本综述旨在识别和评估与虚弱和心血管风险增加相关的表观遗传生物标志物,潜在地促进更精确的患者分层和治疗决策。从2000年到2024年12月27日,使用PubMed、Scopus、Web of Science和Embase数据库进行了两阶段的文献检索。第一阶段确定了报告血液来源的人类样本中与脆弱相关的表观遗传生物标志物的研究。第2阶段通过筛选第1阶段确定的与心血管疾病相关的脆弱性生物标志物来评估心血管相关性。两名独立审稿人进行筛选、数据提取和偏倚风险评估,并通过第三方审稿人解决分歧。主要结局是生物标志物与虚弱严重程度和心血管风险的关联。鉴定的关键表观遗传生物标志物包括microrna(特别是miR-21, miR-146a, miR-451和miR-92a)和DNA甲基化标记(LINE-1甲基化,表观遗传时钟如GrimAge和DunedinPACE,以及可能出现的新型时钟如DNAmCVDscore和吸烟指数)。由于特异性的限制,这些生物标记物在作为多标记物组合的一部分而不是单独使用时最有希望。未来的研究应该验证多标记面板,探索新的生物标记,并评估临床整合,以优化脆弱心血管人群的精准医疗。
Epigenetic Biomarkers of Cardiovascular Risk in Frail Patients-A Scope Review.
Epigenetic biomarkers offer promising potential for early identification and risk stratification of frail individuals susceptible to adverse cardiovascular outcomes. This scope review aimed to identify and evaluate epigenetic biomarkers concurrently associated with frailty and increased cardiovascular risk, potentially facilitating more precise patient stratification and treatment decisions. A two-stage literature search was performed using PubMed, Scopus, Web of Science, and Embase databases from the year 2000 through 27 December 2024. Stage 1 identified studies reporting epigenetic biomarkers associated with frailty in blood-derived human samples. Stage 2 assessed cardiovascular relevance by screening the frailty biomarkers identified in Stage 1 for their documented association with cardiovascular diseases. Two independent reviewers conducted screening, data extraction, and risk-of-bias assessments, resolving disagreements via a third reviewer. The primary outcomes were the association of biomarkers with frailty severity and cardiovascular risk. Key epigenetic biomarkers identified included microRNAs (particularly miR-21, miR-146a, miR-451, and miR-92a) and DNA methylation markers (LINE-1 methylation, epigenetic clocks like GrimAge and DunedinPACE, and possibly novel, emerging clocks like DNAmCVDscore and the Smoking Index). Due to specificity limitations, these biomarkers are most promising when used collectively as part of multimarker panels rather than individually. Future research should validate multimarker panels, explore novel biomarkers, and assess clinical integration to optimize precision medicine in frail cardiovascular populations.
期刊介绍:
Current Issues in Molecular Biology (CIMB) is a peer-reviewed journal publishing review articles and minireviews in all areas of molecular biology and microbiology. Submitted articles are subject to an Article Processing Charge (APC) and are open access immediately upon publication. All manuscripts undergo a peer-review process.